HRS-4508 + trastuzumab

**HRS-4508 + trastuzumab** is an investigational combination therapy consisting of HRS-4508 (a novel small molecule anti-cancer agent) administered together with trastuzumab (a monoclonal antibody targeting HER2). This combination is being studied in clinical trials for the treatment of solid tumors, particularly those resistant to standard anti-HER2 therapies. Trastuzumab binds to the HER2 receptor and blocks its signaling, reducing tumor proliferation. HRS-4508’s detailed mechanism has not been publicly disclosed, but it is used in combinations aiming to improve anti-tumor efficacy, possibly through targeting HER2 or related signaling pathways. The combination seeks to exploit complementary mechanisms against tumor growth, with its activity being evaluated for safety, tolerability, and efficacy[3][5][7].